Spots Global Cancer Trial Database for her2 negative breast cancer
Every month we try and update this database with for her2 negative breast cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer | NCT01918306 | Estrogen Recept... Human Epidermal... Triple Negative... Recurrent Breas... Stage IV Breast... Triple-negative... | cisplatin laboratory biom... pharmacological... dynamic contras... GDC -0941 | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors | NCT03970382 | Solid Tumor | NeoTCR-P1 adopt... nivolumab IL-2 | 18 Years - | PACT Pharma, Inc. | |
| DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs | NCT06176261 | Breast Cancer Breast Cancer F... Metastatic Trip... ER Positive Bre... HER2-negative B... HER2 Negative B... ER-negative Bre... | Datopotamab Der... | 18 Years - | Dana-Farber Cancer Institute | |
| Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients | NCT03650894 | Breast Neoplasm... Breast Cancer Breast Carcinom... Breast Tumor | Nivolumab Ipilimumab Bicalutamide | 18 Years - | Providence Health & Services | |
| GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer | NCT01918306 | Estrogen Recept... Human Epidermal... Triple Negative... Recurrent Breas... Stage IV Breast... Triple-negative... | cisplatin laboratory biom... pharmacological... dynamic contras... GDC -0941 | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer | NCT00703326 | Breast Cancer | ramucirumab (IM... docetaxel Placebo | 18 Years - | Eli Lilly and Company | |
| Exosomal and Free Extracellular RNAs and Proteins as Predictive Biomarkers for HER2 Therapies in Breast Cancer | NCT01840306 | Breast Cancer HER2 Positive B... HER2 Negative B... | Biomarker Analy... | 18 Years - | Cancer Trials Ireland | |
| Monitoring Response to Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer Using High-speed MR Spectroscopic Imaging | NCT03568448 | HER2 Negative B... | Response monito... | 18 Years - | New Mexico Cancer Care Alliance | |
| Anthracycline-free Taxane Based Chemotherapy in Patients With HER2/Neu Negative Early Breast Cancer | NCT01049425 | Primary Breast ... Her2 Non-overex... | Epirubicin Cyclophosphamid... Docetaxel Cyclophosphamid... Docetaxel | 18 Years - 75 Years | West German Study Group | |
| Anthracycline-free Taxane Based Chemotherapy in Patients With HER2/Neu Negative Early Breast Cancer | NCT01049425 | Primary Breast ... Her2 Non-overex... | Epirubicin Cyclophosphamid... Docetaxel Cyclophosphamid... Docetaxel | 18 Years - 75 Years | West German Study Group | |
| Anthracycline-free Taxane Based Chemotherapy in Patients With HER2/Neu Negative Early Breast Cancer | NCT01049425 | Primary Breast ... Her2 Non-overex... | Epirubicin Cyclophosphamid... Docetaxel Cyclophosphamid... Docetaxel | 18 Years - 75 Years | West German Study Group | |
| Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer) | NCT01881230 | Breast Tumor Breast Cancer Cancer of the B... Estrogen Recept... HER2- Negative ... Progesterone Re... Recurrent Breas... Stage IV Breast... Triple-negative... Triple-negative... Metastatic Brea... | nab-Paclitaxel Carboplatin Gemcitabine | 18 Years - | Celgene |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
